All News

Three cycles of chemotherapy were found to face similar results as six cycles among children with retinoblastoma, a type of cancer of the eye.

An expert told CURE that Trodelvy's side effects, such as neutropenia and fatigue, can often be managed through dose adjustments.

In this on-demand webinar series, CURE partnered with UCLA Health and Northside Hospital Cancer Institute to discuss best approaches to tracking side effects for patients with breast cancer.

In this on-demand webinar series, CURE partnered with UCLA Health and Northside Hospital Cancer Institute to discuss side effects of breast cancer treatment.

CURE partnered with UCLA Health and Northside Hospital Cancer Institute for an on-demand webinar series on managing side effects of breast cancer treatment.

Researchers have found an association between baseline circulating tumor cell count and survival in metastatic hormone-sensitive prostate cancer.

When a dear friend told me he has lung cancer, I opened up and shared my own perspective and experience as a survivor of testicular cancer.

Ponsegromab helped patients with cachexia and elevated GDF-15 levels gain weight, increase activity and improve cachexia symptoms, with manageable safety.

If approved by the FDA, Darzalex Faspro may be the first treatment for smoldering multiple myeloma as compared to treating the disease once it progresses.

My daughter's diagnosis of a rare and aggressive brain tumor at 3 years old made me strongly consider whether or not to have her treated with radiation.

MI Cancer Seek has received approval from the FDA as a companion diagnostic test to identify those who may benefit from treatment with targeted therapies.

The CAR-T cell therapy Aucatzyl was approved for relapsed or refractory B-cell precursor acute lymphoblastic leukemia based on findings from the FELIX trial.

Graft-versus-host disease prophylaxis using posttransplant cyclophosphamide remains a valid option for patients with myelodysplastic syndromes.

After cancer treatment, I wanted to go right back to living my life normally, but a fellow CURE blogger’s post reminded me that rest is necessary too.

From James Van Der Beek spreading awareness about colorectal cancer at a younger age to Gerry Connolly’s recent esophageal cancer diagnosis, here’s what’s happening in the cancer space this week.

The combination of Bavencio and gemcitabine showed promising efficacy and safety in certain patients with advanced leiomyosarcoma.

CURE partnered with City of Hope for a webinar to discuss focusing on quality of life when talking with care teams during breast cancer treatment.

In this on-demand webinar series, CURE partnered with City of Hope to discuss how patients with breast cancer can best communicate with their care team.

In this on-demand webinar series, CURE partnered with City of Hope to discuss effective communication when making treatment decisions for breast cancer.

Rates of colorectal cancer diagnoses and deaths are climbing among patients younger than 55, researchers have shown.

As a patient with chronic lymphocytic leukemia, I recently gleaned three new insights from my oncologist and phlebotomist.

In patients with relapsed or refractory multiple myeloma, KRd56 and KRd27 showed similar effectiveness and safety, but other treatment options may be better.

Induction chemotherapy shows significant improvements for survival in patients with locally advanced cervical cancer.

The accelerated approval of Trodelvy for patients with metastatic urothelial cancer has been voluntarily withdrawn.

My quality of life has improved a lot after starting on a BTK inhibitor, but some things will never be the same — like being in crowded places without a mask!

Patients with EGFR-mutant non-small cell lung cancer who are TKI-naïve benefited from receiving the Cyramza-Tagrisso combination versus Tagrisso alone.

Patients with muscle-invasive bladder cancer who underwent whole pelvis radiation showed improved cancer-specific survival and overall survival.

Chemotherapy for three months demonstrates lower side effects, suggesting its use as standard care compared with six months.